Literature DB >> 33555570

Prediction of R0/R+ surgery by different classifications for locally recurrent rectal cancer.

Luca Sorrentino1, Filiberto Belli1, Marcello Guaglio2, Elena Daveri3, Maurizio Cosimelli1.   

Abstract

A widely adopted classification system for locally recurrent rectal cancer (LRRC) is currently missing, and the indication for surgery is not standardized. To evaluate all the published classification systems in a large monocentric cohort of LRRC patients, assessing their capability to predict a radical (R0) resection. A total of 152 consecutive LRRC patients treated at the National Cancer Institute of Milan (NCIM) from 2009 to 2017 were classified according to Pilipshen, Mayo Clinic, Memorial Sloan-Kettering Cancer Center (MSKCC), Wanebo, Yamada, Boyle, Dutch TME Trial, Royal Marsden and National Cancer Institute of Milan (NCIM) classification systems. Central location of LRRC was significantly predictive of R0 resection across all classification systems. R + resection was predicted by the "anterior" category of MSKCC (OR 2.66, p = 0.007), the "S2b" (OR 3.50, p = 0.04) and the "S3" (OR 2.70, p = 0.01) categories of NCIM, "pelvic disease through anastomosis" of Pilipshen (OR 2.89, p = 0.002), "fixed at 2 sites" of Mayo Clinic (OR 2.68, p = 0.019), and "TR4" of Wanebo (OR 3.39, p = 0.002). The NCIM was the most predictive classification for R0 surgery. The NCIM classification seems to be superior among the others in predicting R0 surgery. Generally, lateral invasive and high sacral invasive relapses are associated with reduced probability of R0 surgery and unfavorable outcomes.

Entities:  

Keywords:  Classification; Locally recurrent rectal cancer; R0 surgery

Year:  2021        PMID: 33555570     DOI: 10.1007/s13304-020-00941-0

Source DB:  PubMed          Journal:  Updates Surg        ISSN: 2038-131X


  1 in total

1.  Efficacy and safety of radiotherapy combined with raltitrexed and irinotecan for treating unresectable recurrent colorectal cancer: a single-arm phase II trial.

Authors:  Xinghui Li; Jinwen Shen; Fan Xia; Ji Zhu
Journal:  J Gastrointest Oncol       Date:  2022-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.